Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Bio-Rad Laboratories’ Stock Jumps on Positive Q2 Performance

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 8/3/2025, 9:28 am ET | 5 min
Bio-Rad Laboratories’ Stock Jumps on Positive Q2 Performance Thumbnail

In this article Last trade Aug, 25 1:25 PM

  • BIO-2.55%
    BIO - NYSEBio-Rad Laboratories Inc. Class A
    $296.07-7.75 (-2.55%)
    Volume:  69225
    Float:  21.19M
    $294.39Day Low/High$301.52

Bio-Rad Laboratories Inc.’s stocks have been trading up by 17.34 percent amid positive sentiment from key news developments.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Bio-Rad Laboratories, Inc. is currently displaying mixed financial health in the healthcare sector. While the company has managed to maintain a gross margin of 53.5%, its profitability ratios such as EBIT margin and EBIDTA margin at -106.3% and -103.2% respectively highlight significant operational losses. Despite a strong revenue base of $2.57 billion, ongoing issues such as a negative free cash flow margin (-85.16%) and capital efficiency concerns impact overall profitability. However, the company’s strong liquidity ratios—current ratio of 6 and quick ratio of 4.1—provide it with ample operating flexibility. Furthermore, the company’s low debt-to-equity ratio of 0.21 and high working capital of $2.53 billion suggest a solid balance sheet foundation. Earnings remain slightly pressured, primarily due to high R&D and administrative expenses, limiting its potential to enhance earnings further.
  2. Technical Analysis & Trading Strategy: Recent price action in Bio-Rad indicates an upward trend, with the stock closing at $284.60 on significant volume after a sharp increase from previous sessions. The robust gain aligns with bullish institutional interest, underscoring the validation from upwardly revised price targets by major analysts. The stock shows strong support at the recent closing price of $267 and faces a resistance level near $310, aligned with UBS’s revised price target. Traders may consider initiating long positions should the stock close above $285, with a stop-loss near the support level of $267 to mitigate potential downside risk, favoring the upward breakout potential, especially with the prevailing positive momentum.
  3. Catalysts & Outlook: Bio-Rad Laboratories is positioned for robust growth following its Q2 earnings report, and significant analyst upgrades underscore optimism for the company’s strategic direction. The recent acquisition of Stilla Technologies strengthens its competitive landscape in Droplet Digital PCR. The revised full-year growth guidance from a 1% decline to a projection of flat to 1% growth, alongside an improved operating margin forecast (12-13% from a prior range), portrays an optimistic outlook against industry benchmarks. Despite a challenging earnings environment for the healthcare and medical equipment sectors, Bio-Rad’s progressive steps towards operational efficiency and technological advancement set the stage for a positive trajectory. Support is identified around $265, with the immediate resistance at $310, aligning with analyst upgrades, revealing bullish sentiment and broader anticipation of breakthrough innovations.

Candlestick Chart

Weekly Update Jul 28 – Aug 01, 2025: On Friday, August 01, 2025 Bio-Rad Laboratories Inc. stock [NYSE: BIO] is trending up by 17.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Bio-Rad Laboratories has presented an impressive set of financial figures for Q2 2025, leading to a significant surge in its stock price. The company reported earnings per share (EPS) of $2.61, a notable increase from the consensus estimate of $1.75. This robust performance was underscored by revenues amounting to $651.6M, which significantly exceeded the expected $614.29M. These results showcase Bio-Rad’s operational efficiency and market adaptability.

The acquisition of Stilla Technologies has strategically enhanced Bio-Rad’s product portfolio, particularly strengthening its Droplet Digital PCR offerings. This move is expected to catalyze further market penetration and innovation within the life sciences sector. The introduction of the QX Continuum system and QX700 series has broadened Bio-Rad’s technological capabilities, fostering competitive advantage and enhancing revenue streams.

More Breaking News

Moreover, the upward revisions of the company’s full-year 2025 revenue and operating margin guidance reflect optimism about Bio-Rad’s sustained market growth and profitability. These developments are complemented by a current ratio of 6, indicating solid liquidity and a prudent financial strategy focused on long-term growth and stability.

Conclusion

The recent developments and financial disclosures present a compelling narrative for Bio-Rad Laboratories’ future. Through strategic innovation, judicious acquisitions, and robust Q2 performance, the company positions itself as a formidable player in the biotechnology landscape. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This philosophy resonates with Bio-Rad’s strategy, as their ability to adapt and thrive in an evolving sector remains evident. As trader confidence climbs and market targets are surpassed, stakeholders are likely to witness prolonged value appreciation, driven by Bio-Rad’s consistently strong execution and visionary approach.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

In this article (YTD Performance)

  • BIO-7.52%
    BIO - NYSEBio-Rad Laboratories Inc. Class A
    $296.07-7.75 (-2.55%)
    Volume:  69225
    Float:  21.19M
    $294.39Day Low/High$301.52

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.